Literature DB >> 29998219

Novel tumour antigens and the development of optimal vaccine design.

Victoria A Brentville1, Suha Atabani1, Katherine Cook1, Lindy G Durrant2.   

Abstract

The interplay between tumours and the immune system has long been known to involve complex interactions between tumour cells, immune cells and the tumour microenvironment. The progress of checkpoint inhibitors in the clinic in the last decade has highlighted again the role of the immune system in the fight against cancer. Numerous efforts have been undertaken to develop ways of stimulating the cellular immune response to eradicate tumours. These interventions include the identification of appropriate tumour antigens as targets for therapy. In this review, we summarize progress in selection of target tumour antigen. Targeting self antigens has the problem of thymic deletion of high-affinity T-cell responses leaving a diminished repertoire of low-affinity T cells that fail to kill tumour cells. Thymic regulation appears to be less stringent for differentiation of cancer-testis antigens, as many tumour rejection antigens fall into this category. More recently, targeting neo-epitopes or post-translational modifications such as a phosphorylation or stress-induced citrullination has shown great promise in preclinical studies. Of particular interest is that the responses can be mediated by both CD4 and CD8 T cells. Previous vaccines have targeted CD8 T-cell responses but more recently, the central role of CD4 T cells in orchestrating inflammation within tumours and also differentiating into potent killer cells has been recognized. The design of vaccines to induce such immune responses is discussed herein. Liposomally encoded ribonucleic acid (RNA), targeted deoxyribonucleic acid (DNA) or long peptides linked to toll-like receptor (TLR) adjuvants are the most promising new vaccine approaches. These exciting new approaches suggest that the 'Holy Grail' of a simple nontoxic cancer vaccine may be on the horizon. A major hurdle in tumour therapy is also to overcome the suppressive tumour environment. We address current progress in combination therapies and suggest that these are likely to show the most promise for the future.

Entities:  

Keywords:  T-cell avidity; checkpoint inhibitors; cytotoxic CD4 T cells; neo-epitopes; stress-induced post-translational modifications

Year:  2018        PMID: 29998219      PMCID: PMC5933538          DOI: 10.1177/2515135518768769

Source DB:  PubMed          Journal:  Ther Adv Vaccines Immunother        ISSN: 2515-1355


  134 in total

1.  Immunologic hierarchy, class II MHC promiscuity, and epitope spreading of a melanoma helper peptide vaccine.

Authors:  Yinin Hu; Gina R Petroni; Walter C Olson; Andrea Czarkowski; Mark E Smolkin; William W Grosh; Kimberly A Chianese-Bullock; Craig L Slingluff
Journal:  Cancer Immunol Immunother       Date:  2014-04-23       Impact factor: 6.968

2.  AFP-specific immunotherapy impairs growth of autochthonous hepatocellular carcinoma in mice.

Authors:  Jeannette Cany; Benoît Barteau; Lucile Tran; Vanessa Gauttier; Isabelle Archambeaud; Jean-Pierre Couty; Bruno Turlin; Bruno Pitard; Georges Vassaux; Nicolas Ferry; Sophie Conchon
Journal:  J Hepatol       Date:  2010-08-26       Impact factor: 25.083

3.  PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors.

Authors:  Michael A Curran; Welby Montalvo; Hideo Yagita; James P Allison
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-16       Impact factor: 11.205

4.  A novel cationic liposome reagent for efficient transfection of mammalian cells.

Authors:  X Gao; L Huang
Journal:  Biochem Biophys Res Commun       Date:  1991-08-30       Impact factor: 3.575

Review 5.  Tumor antigens recognized by T lymphocytes.

Authors:  T Boon; J C Cerottini; B Van den Eynde; P van der Bruggen; A Van Pel
Journal:  Annu Rev Immunol       Date:  1994       Impact factor: 28.527

6.  Nivolumab plus ipilimumab in advanced melanoma.

Authors:  Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

Review 7.  Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors.

Authors:  Soumaya Karaki; Marie Anson; Thi Tran; Delphine Giusti; Charlotte Blanc; Stephane Oudard; Eric Tartour
Journal:  Vaccines (Basel)       Date:  2016-11-03

8.  Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients.

Authors:  Paul Sabbatini; Takemasa Tsuji; Luis Ferran; Erika Ritter; Christine Sedrak; Kevin Tuballes; Achim A Jungbluth; Gerd Ritter; Carol Aghajanian; Katherine Bell-McGuinn; Martee L Hensley; Jason Konner; William Tew; David R Spriggs; Eric W Hoffman; Ralph Venhaus; Linda Pan; Andres M Salazar; Catherine Magid Diefenbach; Lloyd J Old; Sacha Gnjatic
Journal:  Clin Cancer Res       Date:  2012-10-02       Impact factor: 12.531

9.  HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial.

Authors:  Mariette I E van Poelgeest; Marij J P Welters; Edith M G van Esch; Linda F M Stynenbosch; Gijs Kerpershoek; Els L van Persijn van Meerten; Muriel van den Hende; Margriet J G Löwik; Dorien M A Berends-van der Meer; Lorraine M Fathers; A Rob P M Valentijn; Jaap Oostendorp; Gert Jan Fleuren; Cornelis J M Melief; Gemma G Kenter; Sjoerd H van der Burg
Journal:  J Transl Med       Date:  2013-04-04       Impact factor: 5.531

10.  Candidate autoantigens identified by mass spectrometry in early rheumatoid arthritis are chaperones and citrullinated glycolytic enzymes.

Authors:  Vincent Goëb; Marlène Thomas-L'Otellier; Romain Daveau; Roland Charlionet; Patrice Fardellone; Xavier Le Loët; François Tron; Danièle Gilbert; Olivier Vittecoq
Journal:  Arthritis Res Ther       Date:  2009-03-10       Impact factor: 5.156

View more
  4 in total

1.  Virus-Like Particle-Drug Conjugates Induce Protective, Long-lasting Adaptive Antitumor Immunity in the Absence of Specifically Targeted Tumor Antigens.

Authors:  Rhonda C Kines; Cynthia D Thompson; Sean Spring; Zhenyu Li; Elisabet de Los Pinos; Stephen Monks; John T Schiller
Journal:  Cancer Immunol Res       Date:  2021-04-14       Impact factor: 12.020

2.  Oncolytic adenovirus drives specific immune response generated by a poly-epitope pDNA vaccine encoding melanoma neoantigens into the tumor site.

Authors:  Alessandra Lopes; Sara Feola; Sophie Ligot; Manlio Fusciello; Gaëlle Vandermeulen; Véronique Préat; Vincenzo Cerullo
Journal:  J Immunother Cancer       Date:  2019-07-10       Impact factor: 13.751

Review 3.  The Role of Toll-Like Receptors in Oncotherapy.

Authors:  Caiqi Liu; Ci Han; Jinfeng Liu
Journal:  Oncol Res       Date:  2019-03-25       Impact factor: 5.574

Review 4.  Sources of Cancer Neoantigens beyond Single-Nucleotide Variants.

Authors:  Aude-Hélène Capietto; Reyhane Hoshyar; Lélia Delamarre
Journal:  Int J Mol Sci       Date:  2022-09-04       Impact factor: 6.208

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.